What is the role of lanreotide in the treatment of gastroenteropancreatic neuroendocrine tumors (NETs)?
Label:chem
Topic
Lanreotide is a somatostatin analog that has been approved for the treatment of NETs based on the CLARINET trial. It is known to bind to somatostatin receptors (SSTR1–5) and regulate tumor proliferation and hormone secretion. However, its effects on the immune system are not well understood.
Answer
Lanreotide primarily acts by inhibiting tumor cell proliferation and hormone secretion through binding to SSTR2 and SSTR5. It also modulates immune function in NET patients, which correlates with clinical response.
Return to Home
Chemical List
Knowledge you may be interested in